PCSK9 inhibitors and ezetimibe with or without statin therapy for cardiovascular risk reduction: a systematic review and network meta-analysis.

What the trial testedas reported · 1,000 people · 2022

Not counted

−13%−20% to −6%

Bigger than 2 in 10 for cardiovascular events

As reported

RR 0.87, 95% CI 0.80–0.94

the abstract, start to end

… ezetimibe to statins reduced MI (RR 0.87 (95% confidence interval 0.80 …

← favours treatmentfavours comparator →

could be chance

Cardiovascular events

RR 0.870.80–0.94

StatinsOther lipid agentsCardiovascular events

1 / 3

2022

2023

2024

2025

2026

this paperpooled ittrialcites it